What Galderma buying ZO Skin Health could change for practices that sell it

Who this is for

This is for the physician or medical professional who owns a practice that sells medical-grade skincare to patients. It also serves the operations lead who orders that stock and sets its shelf prices. Retail here means the practice's skincare product sales.

A practice that stocks ZO will buy from a Galderma brand once the deal closes. Neither Galderma nor the trade press says whether what the practice pays, or who else may sell the line, will change. Patients decide whether they keep buying it there.

What has Galderma said about its ZO Skin Health purchase so far?

Galderma has agreed to buy ZO Skin Health from Blackstone Tactical Opportunities and the Obagi family for $1.5 billion, all in cash. Inside MedSpa reported the terms on October 17, 2026, citing Pulse 2.0.¹

Inside MedSpa expects the deal to close in the fourth quarter of 2026 or early 2027, pending regulatory sign-off. It calls ZO the Swiss company's second major skincare purchase in recent years, after Alastin.¹

Galderma's announcement, dated October 14, 2026, describes ZO as a physician-dispensed skincare brand, meaning one sold to patients through medical offices. Galderma expects the purchase to be core EPS neutral in the first full year after closing. It leaves core earnings per share unchanged.²

Galderma also plans to raise commercial investment during its first year of ownership. In its words, that spending is meant "to strengthen the foundation for renewed growth beginning in the second year following closing."²

What terms does Galderma's Alastin line set for practices that resell it?

Inside MedSpa names Alastin as Galderma's earlier skincare purchase. Alastin publishes the terms it sets for practices, in a sales policy that shows how a Galderma skincare brand already sells through medical offices.^1,3

The policy tells patients they can buy Alastin directly from Alastin. They may also buy from network healthcare providers who resell it, which Alastin calls authorized resellers.³

A reseller may sell in the office or online, through a website the practice owns or controls.³

Both channels carry conditions. A reseller may not sell Alastin "without the participation of a practicing physician with a valid DEA number or Medical Education number." It must also give customers access to a physician or skin care professional in connection with the sale, service and support of the product. It may not sell unboxed product.³

Inside MedSpa's coverage does not say whether ZO's reseller terms will change after closing. Alastin's policy covers Alastin only.

The federal rules the FDA describes for cosmetics concern the product and its label. Its labeling guide rests on the Federal Food, Drug, and Cosmetic Act of 1938, which bars moving adulterated or misbranded cosmetics across state lines.⁴

The guide also cites the Fair Packaging and Labeling Act. That law requires labels to give accurate information about the quantity of contents.⁴

Do patients who trust a dermatologist buy skincare at the practice?

A 2019 survey by the American Society for Dermatologic Surgery put dermatologists first among influences on skincare purchases, and its 2021 release title says so. A Korean study found patients trusted dermatologists most. Yet they named friends more often as what drove purchases.

The American Society for Dermatologic Surgery (ASDS) received 3,645 responses to its 2019 consumer survey, run online from July 30 to August 27 by Survata. The Hospitalist community reported the results.⁵

Respondents could choose from 14 factors. Dermatologists were the top influence on skincare purchases, picked by 45%, against 32% for friends and 28% for social media.⁵

The society's 2021 survey ran online from October 20 to November 9, 2021, through PureSpectrum, and received 3,527 responses. Its release is titled "Dermatologists Are the Leading Influencer for Cosmetic Procedures and Skin Care Decisions."⁶

The 2021 release, as read, gives no percentage for skincare decisions. Its title and the 2019 survey's data points point the same way.

A 2020 study in Annals of Dermatology surveyed Korean adults and split the decision in two. Respondents named the dermatologist the most reliable source of skincare recommendations, at 41.55%.⁷

Asked what most influenced what they bought, 40.11% chose friends or acquaintances and 20.20% chose dermatologists. Dermatologists' clinics were where 7.41% bought, against 27.64% at specialized skincare shops and 8.83% on online sites.⁷

Korean shoppers buy largely through specialized skincare shops. Their habits may differ from those of a US practice's patients. The 2019 ASDS survey asked what influences skincare purchases, and dermatologists came first. In contrast, the Korean study asked separately about reliability, influence and where people bought, and friends or acquaintances led on influence. The two surveyed different populations with different questions.

A 2025 white paper from the FIT Center for Fashion/Fashion Management cites Prime Matter Labs for one more data point. It reports that 63% of consumers are more likely to trust beauty brands endorsed by medical professionals. The population behind that number is not stated.⁸

What do benchmarks show about physician-dispensed skincare retail revenue?

CorralData, a vendor, put injectables at 44.0% of recorded revenue in Q3 2026 at the median operator. That made them the largest category.⁹

A 2021 article from the American Med Spa Association (AmSpa) said injectables often account for 40% to 60% of an aesthetics practice's monthly revenue. It gives no sample.¹⁰

CorralData's H1 2026 benchmark does not report retail on its own. It places retail in an "other" category, with memberships, packages, procedure fees and wellness, at 27.2% of median revenue.¹¹

American Spa wrote on October 20, 2026, that revenue "may be growing but attracting new patients isn't necessarily what's driving the gains." It was reporting CorralData's Q3 data.¹²

Skytale Group, a vendor, analyzed skincare buying in medspas. In its data, the 17% of patients who buy skincare three or more times generate nearly half of skincare revenue. Skytale does not say whether that revenue is the practices' or the brands'.¹³

AmSpa's 2025 article quotes Terri Wojak of True U on return rates. By her account, a client who buys no product with a service returns to the practice 10% of the time. A client who buys one product returns 30% of the time, and for one who buys two, the rate can be as high as 60%. She gives no time window for those returns.¹⁴

Neither Skytale nor Wojak gives a sample size. Wojak leaves open whether buying product causes the return visits. A patient already planning to return may also be likelier to buy.

Repeat buyers buy most often. By our reading of Skytale's data, they would meet any change in ZO's price or reseller terms under Galderma first.

Which ZO numbers does only the practice have?

No source gives ZO's wholesale price. None gives a practice's margin on ZO or its retail sales by brand. Those numbers sit with each practice and its ZO account.

Two records would answer this. Point-of-sale and booking data show ZO's share of retail sales, how many ZO buyers rebuy, and whether they rebook treatments. The account agreement before and after closing shows any change in price, online-sale rules or physician conditions.

About this review

We read 15 sources in October 2026. They were Galderma's announcement, two trade-press articles, Alastin's sales policy and the FDA's cosmetics labeling guide. They included two peer-reviewed studies, two reports of ASDS surveys, two AmSpa articles, two CorralData benchmarks, one Skytale Group analysis and one FIT white paper. Each data point appears under its publisher's name. We computed no gap or ratio between sources.

The 2001 Archives of Dermatology study was read in its abstract only, and none of its data points are used here.¹⁵ The FDA labeling guide was read in part. ZO's current reseller terms, its wholesale prices and any FTC, Department of Justice or state document on the deal were not among the sources found.

Fractional Aesthetics is a growth strategy practice for aesthetic medical businesses.